Application of a physiologically based pharmacokinetic model of rivaroxaban to prospective simulations of drug–drug–disease interactions with protein kinase inhibitors in cancer‐associated venous thromboembolism
Author:
Affiliation:
1. Department of Pharmacy, Faculty of Science National University of Singapore Singapore Singapore
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15158
Reference70 articles.
1. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update;Key NS;J Clin Oncol,2020
2. Cancer‐associated thrombosis: The when, how and why;Fernandes CJ;Eur Respir Rev,2019
3. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer;Farge D;Lancet Oncol,2019
4. Rivaroxaban for thromboprophylaxis in high‐risk ambulatory patients with cancer;Khorana AA;N Engl J Med,2019
5. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans;Weinz C;Drug Metab Dispos,2009
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Mathematical modeling of cardio-oncology: Modeling the systemic effects of cancer therapeutics on the cardiovascular system;Seminars in Cancer Biology;2023-12
2. Application of physiologically based pharmacokinetics modeling in the research of small-molecule targeted anti-cancer drugs;Cancer Chemotherapy and Pharmacology;2023-07-19
3. Effect of Clarithromycin, a Strong CYP3A and P-glycoprotein Inhibitor, on the Pharmacokinetics of Edoxaban in Healthy Volunteers and the Evaluation of the Drug Interaction with Other Oral Factor Xa Inhibitors by a Microdose Cocktail Approach;Cardiovascular Drugs and Therapy;2023-03-04
4. Development and verification of a physiologically based pharmacokinetic model of dronedarone and its active metabolite N‐desbutyldronedarone: Application to prospective simulation of complex drug–drug interaction with rivaroxaban;British Journal of Clinical Pharmacology;2023-02-07
5. Machine learning for metabolomics research in drug discovery;Intelligence-Based Medicine;2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3